MentionFox
Home › Who owns › InMed Pharmaceuticals Inc.
Owners, funding and legal record

Who owns InMed Pharmaceuticals Inc.? Owners, funding and legal record

Before you sign with, sell to or invest in InMed Pharmaceuticals Inc.

MentionFox check on InMed Pharmaceuticals Inc.: no red flags found in 19 sources; 1 item to note (checked 16 November 2026). mentionfox.com/c/who-owns/mentari-therapeutics

  • Note: Layoff plan disclosed Mar 2026 (filing)

Check InMed Pharmaceuticals Inc. before you sign, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about InMed Pharmaceuticals Inc.?

InMed Pharmaceuticals Inc. is a publicly traded company (Nasdaq: INM). Vivo Opportunity Fund Holdings, L.P. reports 21.7% on Schedule 13D, the largest active stake (Schedule 13D, filed 2026-06-10).

As of November 16, 2026, InMed Pharmaceuticals Inc. is a publicly traded company (Nasdaq: INM). The largest holder reporting an active stake on Schedule 13D is Vivo Opportunity Fund Holdings, L.P., at 21.7%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include ADAR1 Capital (17.2%), Sabby Management, LLC (9.9%), Squadron Master Fund LP (9.8%) (Schedule 13D, June 10, 2026).

Fairmount Funds Management LLC also filed stake reports on 14 other companies ↓

Is this your company?

About to sign with, pay or invest in InMed Pharmaceuticals Inc.? See the free Snapshot first.

Watch InMed Pharmaceuticals Inc.

Free to see. No signup.

Is InMed Pharmaceuticals Inc. a real, registered company?

Before you sign or pay

Who are InMed Pharmaceuticals Inc.'s owners and officers?

InMed Pharmaceuticals Inc.: industry Pharmaceutical Preparations (Schedule 13G, 2026-11-13).

Officers and directors, each with the role and the filing that names them:

ReportHolderShare
Schedule 13G, 2026-11-13Deep Track Capital, LP5.64%
Schedule 13G, 2026-11-13Commodore Capital LP5.6%
Schedule 13D, 2026-11-12Fairmount Funds Management LLC19.99%
Schedule 13G/A, 2026-10-07Adar1 Capital Management, LLC17.2%
Schedule 13G, 2026-08-14Ikarian Capital, LLC4.2%
Schedule 13D, 2026-06-10Vivo Opportunity Fund Holdings, L.P.21.7%
Schedule 13G, 2026-06-05Adar1 Capital Management, LLC24.1%
Schedule 13G, 2026-05-27Squadron Master Fund LP9.8%
Schedule 13G, 2026-01-20Sabby Management, LLC9.9%

Questions about who owns InMed Pharmaceuticals Inc.

Who owns InMed Pharmaceuticals Inc.?

On this page, 7 holders' latest ownership filings report 5% or more of InMed Pharmaceuticals Inc.: Vivo Opportunity Fund Holdings, L.P. (21.7%, Schedule 13D, filed 2026-06-10), Fairmount Funds Management LLC (19.99%, Schedule 13D, filed 2026-11-12), Adar1 Capital Management, LLC (17.2%, Schedule 13G/A, filed 2026-10-07), Sabby Management, LLC (9.9%, Schedule 13G, filed 2026-01-20) and Squadron Master Fund LP (9.8%, Schedule 13G, filed 2026-05-27); 2 more are listed above.

Who are the largest shareholders of InMed Pharmaceuticals Inc.?

By the share each holder's latest filing reports, the largest holders of InMed Pharmaceuticals Inc. on this page are Vivo Opportunity Fund Holdings, L.P. (21.7%), Fairmount Funds Management LLC (19.99%) and Adar1 Capital Management, LLC (17.2%).

When did Vivo Opportunity Fund Holdings, L.P. buy into InMed Pharmaceuticals Inc.?

The filings give report dates, not purchase dates. The earliest filing from Vivo Opportunity Fund Holdings, L.P. on this page is the Schedule 13D, filed 2026-06-10, reporting 21.7%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Want the whole picture on InMed Pharmaceuticals Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on InMed Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on InMed Pharmaceuticals Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    19 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.
FiledPersonRoleChangeEffective
Form 8-K, 2026-11-10Gregory DivisPresident and Chief Executive Officerappointed
Form 8-K, 2026-11-10Brett Hagenappointed

Which insiders own InMed Pharmaceuticals Inc. shares?

Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.

Shares outstanding: 5,493,735 as of 2026-10-30, from the company's latest SEC cover page.

How much has InMed Pharmaceuticals Inc. raised?

FiledSoldOffered
Form D, 2022-12-06$6M$6M

Latest IPO step: InMed Pharmaceuticals Inc. amended its IPO registration (S-1/A, 2025-08-01).

IPO filings: S-1/A, 2025-08-01, S-1, 2025-07-09, S-1/A, 2024-12-30, S-1, 2024-12-23; ticker INM on Nasdaq Capital Market.

Acquisitions reported on Form 8-K, Item 2.01: acquired Mentari (2026-11-10).

Red flags found

1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-03-06).

Keep reading

More on InMed Pharmaceuticals Inc. and the records around it.

InMed Pharmaceuticals Inc. elsewhere on the record

Companies that share a holder

Related pages

Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.

Not for employment, credit, insurance or tenancy decisions.

Cite this page

Permanent URL: https://mentionfox.com/who-owns/mentari-therapeutics
Last updated 2026-11-16
Who owns InMed Pharmaceuticals Inc.? Owners, funding and legal record. MentionFox, 2026-11-16. https://mentionfox.com/who-owns/mentari-therapeutics